AR126893A1 - Compuestos de aminopiridina que contienen heteroarilo de 6 miembros como inhibidores de egfr - Google Patents
Compuestos de aminopiridina que contienen heteroarilo de 6 miembros como inhibidores de egfrInfo
- Publication number
- AR126893A1 AR126893A1 ARP220102311A ARP220102311A AR126893A1 AR 126893 A1 AR126893 A1 AR 126893A1 AR P220102311 A ARP220102311 A AR P220102311A AR P220102311 A ARP220102311 A AR P220102311A AR 126893 A1 AR126893 A1 AR 126893A1
- Authority
- AR
- Argentina
- Prior art keywords
- membered heteroaryl
- pharmaceutically acceptable
- aminopyridine compounds
- egfr inhibitors
- administering
- Prior art date
Links
- -1 AMINOPYRIDINE COMPOUNDS Chemical class 0.000 title abstract 2
- 229940121647 egfr inhibitor Drugs 0.000 title 1
- 239000012472 biological sample Substances 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 abstract 2
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 abstract 2
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 102000001253 Protein Kinase Human genes 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 108060006633 protein kinase Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La presente invención proporciona nuevos compuestos de aminopiridina que contienen heteroarilo de 6 miembros y composiciones farmacéuticamente aceptables de los mismos que exhiben actividad de inhibición contra ciertas formas mutadas de EGFR. Reivindicación 24: Un método para tratar una enfermedad mediada por proteína quinasa en un sujeto que lo necesite, que comprende administrar a dicho sujeto una cantidad terapéuticamente eficaz de un compuesto de cualquiera de las reivindicaciones 1 a 23, o una sal farmacéuticamente aceptable del mismo. Reivindicación 29: Un método para inhibir selectivamente al menos un mutante de EGFR, en una muestra biológica o en un paciente, que comprende poner en contacto la muestra biológica o administrar a un paciente un compuesto de cualquiera de las reivindicaciones 1 a 23, o una de sus sales farmacéuticamente aceptables.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163237653P | 2021-08-27 | 2021-08-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR126893A1 true AR126893A1 (es) | 2023-11-29 |
Family
ID=85321858
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP220102311A AR126893A1 (es) | 2021-08-27 | 2022-08-26 | Compuestos de aminopiridina que contienen heteroarilo de 6 miembros como inhibidores de egfr |
| ARP220102309A AR126889A1 (es) | 2021-08-27 | 2022-08-26 | Compuestos de aminopiridina que contienen heteroarilo de 5 miembros como inhibidores de egfr |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP220102309A AR126889A1 (es) | 2021-08-27 | 2022-08-26 | Compuestos de aminopiridina que contienen heteroarilo de 5 miembros como inhibidores de egfr |
Country Status (5)
| Country | Link |
|---|---|
| US (3) | US20230085912A1 (es) |
| KR (1) | KR20240052796A (es) |
| AR (2) | AR126893A1 (es) |
| TW (2) | TW202317105A (es) |
| WO (3) | WO2023027515A1 (es) |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6884804B2 (en) * | 2001-05-16 | 2005-04-26 | Vertex Pharmaceuticals Incorporated | Inhibitors of Src and other protein kinases |
| BRPI0406809A (pt) | 2003-01-17 | 2005-12-27 | Warner Lambert Co | Heterociclos substituìdos de 2-aminopiridina como inibidores da proliferação celular |
| KR20070030196A (ko) | 2004-04-13 | 2007-03-15 | 이카겐, 인코포레이티드 | 칼륨 이온 채널 조절제로서의 폴리시클릭 피리딘 |
| WO2005121126A1 (en) * | 2004-04-13 | 2005-12-22 | Icagen, Inc. | Polycyclic pyrazines as potassium ion channel modulators |
| CA2561895A1 (en) | 2004-04-13 | 2005-10-27 | Icagen, Inc. | Polycyclic pyrimidines as potassium ion channel modulators |
| GB0719644D0 (en) | 2007-10-05 | 2007-11-14 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
| WO2013192125A1 (en) * | 2012-06-20 | 2013-12-27 | Merck Sharp & Dohme Corp. | Pyrazolyl derivatives as syk inhibitors |
| RU2015147601A (ru) * | 2013-05-01 | 2017-06-05 | Ф. Хоффманн-Ля Рош Аг | С-связанные гетероциклоалкилзамещенные пиримидины и их применения |
| CN104761544B (zh) | 2014-01-03 | 2019-03-15 | 北京轩义医药科技有限公司 | Egfr酪氨酸激酶的临床重要突变体的选择性抑制剂 |
| CN106588885B (zh) | 2016-11-10 | 2019-03-19 | 浙江大学 | 2-取代芳环-嘧啶类衍生物及制备和应用 |
| IL275490B2 (en) | 2017-12-22 | 2024-05-01 | Ravenna Pharmaceuticals Inc | Aminopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors |
| WO2019222538A1 (en) * | 2018-05-16 | 2019-11-21 | The University Of North Carolina At Chapel Hill | Aminopyrimidines and aminopyridines as mertk inhibitors and their application in cancer treatment |
| KR102297587B1 (ko) * | 2018-08-07 | 2021-09-06 | 재단법인 대구경북첨단의료산업진흥재단 | 치환된 n-헤테로아릴 유도체, 이의 제조방법 및 이를 유효성분으로 포함하는 암의 예방 또는 치료용 약학적 조성물 |
| BR112021019508A2 (pt) * | 2019-04-02 | 2022-02-01 | Hinova Pharmaceuticals Inc | Composto de amina aromática e uso do mesmo na preparação de reguladores e inibidores duplos de ar e brd4 |
| TW202112767A (zh) * | 2019-06-17 | 2021-04-01 | 美商佩特拉製藥公司 | 作為磷脂酸肌醇磷酸激酶抑制劑之胺基吡啶衍生物 |
| WO2020259683A1 (zh) * | 2019-06-28 | 2020-12-30 | 成都赜灵生物医药科技有限公司 | 2，4-二取代嘧啶衍生物及其制备方法和用途 |
| CA3161746A1 (en) * | 2019-11-15 | 2021-05-20 | The University Of North Carolina At Chapel Hill | Aryl aminopyrimidines as dual mertk and tyro3 inhibitors and methods thereof |
| WO2021159993A1 (en) * | 2020-02-14 | 2021-08-19 | Pharmablock Sciences (Nanjing) , Inc. | Inhibitors of interleukin-1 receptor associated kinase (irak) /fms-like receptor tyrosine kinase (flt3), pharmaceutical products thereof, and methods thereof |
-
2022
- 2022-08-24 TW TW111131848A patent/TW202317105A/zh unknown
- 2022-08-24 TW TW111131847A patent/TW202328096A/zh unknown
- 2022-08-25 WO PCT/KR2022/012693 patent/WO2023027515A1/en active Application Filing
- 2022-08-25 WO PCT/KR2022/012694 patent/WO2023027516A1/en active Application Filing
- 2022-08-25 KR KR1020247009716A patent/KR20240052796A/ko unknown
- 2022-08-25 WO PCT/KR2022/012695 patent/WO2023027517A1/en active Application Filing
- 2022-08-26 AR ARP220102311A patent/AR126893A1/es unknown
- 2022-08-26 AR ARP220102309A patent/AR126889A1/es unknown
- 2022-08-26 US US17/822,443 patent/US20230085912A1/en active Pending
- 2022-08-26 US US17/822,438 patent/US11945798B2/en active Active
- 2022-08-26 US US17/822,445 patent/US20230090406A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2023027515A1 (en) | 2023-03-02 |
| KR20240052796A (ko) | 2024-04-23 |
| AR126889A1 (es) | 2023-11-22 |
| US11945798B2 (en) | 2024-04-02 |
| TW202328096A (zh) | 2023-07-16 |
| WO2023027516A1 (en) | 2023-03-02 |
| TW202317105A (zh) | 2023-05-01 |
| US20230090406A1 (en) | 2023-03-23 |
| US20230086795A1 (en) | 2023-03-23 |
| WO2023027517A1 (en) | 2023-03-02 |
| US20230085912A1 (en) | 2023-03-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR116753A1 (es) | Proceso de preparación de un derivado de pirazolsulfonilamida | |
| EA202090955A1 (ru) | Способы применения ингибиторов ehmt2 в лечении или предупреждении нарушений со стороны крови | |
| BR112023020483A2 (pt) | Compostos para inibir nlrp3 e usos dos mesmos | |
| CL2021001575A1 (es) | Pirazolopirimidinas sustituidas y purinas sustituidas y su uso como inhibidores de proteasa procesadora específica de ubiquitina 1 (usp1) | |
| MX2022015812A (es) | Inhibidores de cisteina proteasas y sus metodos de uso. | |
| CL2020001019A1 (es) | Métodos de uso de inhibidores de ehmt2 para tratar o prevenir trastornos sanguíneos. | |
| CO2023000199A2 (es) | Péptidos funcionalizados como agentes antivirales | |
| AR109605A2 (es) | Método para tratar enfermedades vasculares periféricas, composición y utilización | |
| CO2020013600A2 (es) | Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de jak | |
| NI201100147A (es) | Métodos para tratar infartos agudos de miocardio y trastornos relacionados. | |
| UY38613A (es) | Inhibidores de la proteína tirosina fosfatasa y mètodos de uso de los mismos | |
| CO2023008018A2 (es) | Nuevos agentes antivirales derivados de la espiropirrolidina | |
| DOP2018000150A (es) | Compuestos de diamina-arilsulfonamida sustituidos con hidroxialquilamina e hidroxicicloalquilamina con actividad selectiva en canales de sodio activados por voltaje | |
| AR105712A1 (es) | Composiciones de insulina de rápida acción | |
| AR048439A1 (es) | Composiciones farmaceuticas y metodos para tratar la infeccion por vih | |
| SI2903616T1 (en) | The use of masitinib in combination with gemcitabine for the treatment of a subgroup of patients suffering from foot-and-mouth disease | |
| CL2020002465A1 (es) | Método de tratamiento de enfermedad fibrótica | |
| BR112023021131A2 (pt) | Tratamento de tremor essencial | |
| CL2023002746A1 (es) | Inhibidores de la línea 1 para tratar enfermedades del snc y sistémicas | |
| CO2019004004A2 (es) | Composición farmacéutica y método para el tratamiento de la enfermedad del hígado graso no alcohólico | |
| CL2022000214A1 (es) | Inhibidores de enzimas | |
| MX2021007330A (es) | Composiciones y métodos terapéuticos para tratar cáncer usando ácido 6, 8-bis-benciltio-octanoico y un inhibidor de autofagia. | |
| AR127247A1 (es) | Inhibidores de cdk2 de ciclopentilpirazol | |
| CO2024005925A2 (es) | Moléculas pequeñas para el tratamiento del cáncer | |
| AR126893A1 (es) | Compuestos de aminopiridina que contienen heteroarilo de 6 miembros como inhibidores de egfr |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |